Author

Shizhong Ke

Observed name: Ke, Shizhong

Institutions: Fujian Medical University, Beth Israel Deaconess Medical Center, Harvard University, First Affiliated Hospital of Fujian Medical University

Observed institutions: Broad Institute, Fujian Medical University, Beth Israel Deaconess Medical Center, Harvard University, Shanghai Jiao Tong University, Renji Hospital, Beth Israel Deaconess Hospital, Shanghai Cancer Institute, First Affiliated Hospital of Fujian Medical University, State Key Laboratory of Oncogene and Related Genes

OpenAlex ID: A5035640126

Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy

2021 · Kazuhiro Koikawa, Shin Kibe, et al. · Cell · 233

PARP-inhibition reprograms macrophages toward an anti-tumor phenotype

2022 · Lin Wang, Dan Wang, et al. · Cell Reports · 55

Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer

2021 · Fabin Dang, Li Nie, et al. · Nature Communications · 48

Erythrocytosis in hepatocellular carcinoma portends poor prognosis by respiratory dysfunction secondary to mitochondrial DNA mutations

2016 · Shizhong Ke, Shuzhen Chen, et al. · Hepatology · 25

Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry

2024 · Shizhong Ke, Fabin Dang, et al. · Nature Communications · 13

Reciprocal inhibition of PIN1 and APC/CCDH1 controls timely G1/S transition and creates therapeutic vulnerability

2023 · Shizhong Ke, Fabin Dang, et al. · Research Square · 3

Abstract 7903: MiR-362-3p enhances platinum response in breast cancer

2026 · Zhaoji Liu, Shizhong Ke, et al. · Cancer Research

The miR-362-3p/ BCLAF1 axis regulates cisplatin sensitivity and metastatic progression in triple-negative breast cancer

2026 · Zhaoji Liu, Catherine Wu, et al. · medRxiv

Works count: 10

Citation count: 377

H-index: 5

I10-index: 5